{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T07:03:21Z","timestamp":1791443001413,"version":"4.3.3"},"reference-count":68,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"name":"Scientific Centre of Excellence for Basic, Clinical and Translational Neuroscience","award":["GA KK01.1.1.01.0007"],"award-info":[{"award-number":["GA KK01.1.1.01.0007"]}]},{"name":"European Union through the European Regional Development Fund"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.pnpbp.2020.110042","type":"journal-article","created":{"date-parts":[[2020,7,17]],"date-time":"2020-07-17T08:07:56Z","timestamp":1594973276000},"page":"110042","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone"],"prefix":"10.1016","volume":"104","author":[{"given":"Lana","family":"Ganoci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vladimir","family":"Trkulja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"\u017divkovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tamara","family":"Bo\u017eina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"\u0160agud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mila","family":"Lovri\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Bo\u017eina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2020.110042_bb0005","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1177\/0269881105053306","article-title":"Influence of age and gender on risperidone plasma concentrations","volume":"19","author":"Aichhorn","year":"2005","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0010","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/FPC.0b013e3283659a94","article-title":"CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment","volume":"23","author":"Almoguera","year":"2013","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.pnpbp.2020.110042_bb0015","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1097\/00007691-200312000-00003","article-title":"Intra- and interindividual variations in steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone in schizophrenic patients treated chronically with various doses of risperidone","volume":"25","author":"Aravagiri","year":"2003","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0020","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.ab.2004.07.030","article-title":"Genotyping of the triallelic variant G2677T\/A in MDR1 using LightCycler with locked-nucleic-acid-modified hybridization probes","volume":"334","author":"Arjomand-Nahad","year":"2004","journal-title":"Anal. Biochem."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0025","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4088\/JCP.v60n0709","article-title":"A pilot study on risperidone metabolism: the role of cytochromes P450 2D6 and 3A","volume":"60","author":"Bork","year":"1999","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2020.110042_bb0030","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/S0024-3205(02)01680-6","article-title":"In vitro P-glycoprotein affinity for atypical and conventional antipsychotics","volume":"71","author":"Boulton","year":"2002","journal-title":"Life Sci."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0035","series-title":"Standardizing CYP2D6 Genotype to Phenotype Translation\u00a0: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group 13","first-page":"116","author":"Caudle","year":"2020"},{"key":"10.1016\/j.pnpbp.2020.110042_bb0040","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1097\/JCP.0b013e31828f62cd","article-title":"Pharmacogenetic study on risperidone long-acting injection: influence of cytochrome P450 2D6 and pregnane X receptor on risperidone exposure and drug-induced side-effects","volume":"33","author":"Choong","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0045","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4088\/JCP.v66n0103","article-title":"The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation","volume":"66","author":"de Leon","year":"2005","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.pnpbp.2020.110042_bb0050","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1055\/s-2007-973836","article-title":"A study of genetic (CYP2D6 and ABCB1) and environmental (drug inhibitors and inducers) variables that may influence plasma risperidone levels","volume":"40","author":"de Leon","year":"2007","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pnpbp.2020.110042_bb0055","series-title":"Xenobiotic-Metabolizing Enzymes and Transporters in the Normal Human Brain\u00a0: Regional and Cellular Mapping as a Basis for Putative Roles in Cerebral Function","first-page":"1528","volume":"37","author":"Dutheil","year":"2009"},{"key":"10.1016\/j.pnpbp.2020.110042_bb0060","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.schres.2003.11.001","article-title":"Pharmacokinetics and tolerability of long-acting risperidone in schizophrenia","volume":"70","author":"Eerdekens","year":"2004","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0065","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2217\/pgs.12.187","article-title":"CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy","volume":"14","author":"Elens","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pnpbp.2020.110042_bb0070","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/PL00005334","article-title":"Metabolism of risperidone to 9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4","volume":"359","author":"Fang","year":"1999","journal-title":"Naunyn Schmiedeberg\u2019s Arch. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0075","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1111\/j.1365-2125.2008.03276.x","article-title":"Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements from the CATIE study","volume":"66","author":"Feng","year":"2008","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0080","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/FPC.0000000000000305","article-title":"PharmGKB summary\u00a0: very important pharmacogene information for ABCG2","volume":"27","author":"Fohner","year":"2017","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.pnpbp.2020.110042_bb0085","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s11095-008-9752-7","article-title":"Major SNP (Q141K) variant of human ABC transporter ABCG2 undergoes lysosomal and proteasomal degradations","volume":"26","author":"Furukawa","year":"2009","journal-title":"Pharm. Res."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0090","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1515\/dmpt-2016-0024","article-title":"Genetic polymorphisms of cytochrome P450 enzymes: CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5 in the Croatian population","volume":"32","author":"Ganoci","year":"2017","journal-title":"Drug Metab. Pers. Ther."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0095","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1017\/S1461145704004924","article-title":"Pharmacokinetics and D2 receptor occupancy of long-acting injectable risperidone (Risperdal Consta) in patients with schizophrenia","volume":"8","author":"Gefvert","year":"2005","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0100","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/clpt.2013.86","article-title":"Transporters in drug development and clinical pharmacology","volume":"94","author":"Giacomini","year":"2013","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0105","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.2174\/1389200219666180629121033","article-title":"Relevance of breast cancer resistance protein to brain distribution and central acting drugs: a pharmacokinetic perspective","volume":"19","author":"Goncalves","year":"2018","journal-title":"Curr. Drug Metab."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0110","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1097\/FTD.0b013e3181858ca9","article-title":"ABCB1 polymorphisms influence steady-state plasma levels of 9-hydroxyrisperidone and risperidone active moiety","volume":"30","author":"Gunes","year":"2008","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0115","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3109\/15622975.2012.739708","article-title":"World Federation of Societies of biological psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects","volume":"14","author":"Hasan","year":"2013","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2020.110042_bb0120","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1080\/13651500310002986","article-title":"The use of the Simpson Angus scale for the assessment of movement disorder: a training guide","volume":"7","author":"Hawley","year":"2003","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0125","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1097\/JCP.0b013e3181c17df0","article-title":"Impact of CYP2D6 genotype on steady-state serum concentrations of risperidone and 9-hydroxyrisperidone in patients using long-acting injectable risperidone","volume":"29","author":"Hendset","year":"2009","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0130","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.pnpbp.2020.110042_bb0135","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.bcp.2017.10.004","article-title":"BCRP\/ABCG2 and high-alert medications: biochemical, pharmacokinetic, pharmacogenetic, and clinical implications","volume":"147","author":"Hira","year":"2018","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0140","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/FPC.0b013e3283385a1c","article-title":"Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein)","volume":"21","author":"Hodges","year":"2011","journal-title":"Pharmacogenet. Genomics"},{"key":"10.1016\/j.pnpbp.2020.110042_bb0145","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2133\/dmpk.DMPK-11-RV-098","article-title":"Functional significance of genetic polymorphisms in P-glycoprotein (MDR1, ABCB1) and breast cancer resistance protein (BCRP, ABCG2)","volume":"27","author":"Ieiri","year":"2012","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0150","doi-asserted-by":"crossref","first-page":"11825","DOI":"10.1073\/pnas.90.24.11825","article-title":"Inherited amplification of an active gene in the cytochrome P450 CYP2D locus as a cause of ultrarapid metabolism of debrisoquine","volume":"90","author":"Johansson","year":"1993","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0155","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1007\/s00228-010-0850-1","article-title":"The role of CYP2D6 and ABCB1 pharmacogenetics in drug-naive patients with first-episode schizophrenia treated with risperidone","volume":"66","author":"Jovanovic","year":"2010","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0160","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1016\/S2215-0366(19)30088-4","article-title":"Effect of CYP2D6 genotype on exposure and efficacy of risperidone and aripiprazole: a retrospective, cohort study","volume":"6","author":"Jukic","year":"2019","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.pnpbp.2020.110042_bb0165","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.pnpbp.2010.01.005","article-title":"MDR1 gene polymorphisms and response to acute risperidone treatment","volume":"34","author":"Kastelic","year":"2010","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.pnpbp.2020.110042_bb0170","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The positive and negative syndrome scale (PANSS) for schizophrenia","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr. Bull."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0175","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/bcp.13646","article-title":"Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy","volume":"84","author":"Klarica Domjanovi\u0107","year":"2018","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0180","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1023\/B:PHAM.0000045245.21637.d4","article-title":"Functional analysis of SNPs variants of BCRP\/ABCG2","volume":"21","author":"Kondo","year":"2004","journal-title":"Pharm. Res."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0185","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.schres.2005.04.008","article-title":"What does the PANSS mean?","volume":"79","author":"Leucht","year":"2005","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0190","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.schres.2007.09.006","article-title":"Extrapolation between measures of symptom severity and change: an examination of the PANSS and CGI","volume":"98","author":"Levine","year":"2008","journal-title":"Schizophr. Res."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0195","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.ejps.2010.06.016","article-title":"A population pharmacokinetic evaluation of the influence of CYP2D6 genotype on risperidone metabolism in patients with acute episode of schizophrenia","volume":"41","author":"Locatelli","year":"2010","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0200","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1097\/FTD.0b013e31826517c6","article-title":"Association between lamotrigine concentrations and ABCB1 polymorphisms in patients with epilepsy","volume":"34","author":"Lovric","year":"2012","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0205","first-page":"1134","article-title":"Absorption, metabolism, and excretion of risperidone in humans","volume":"21","author":"Mannens","year":"1993","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0210","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1007\/s40262-018-0664-3","article-title":"Clinical pharmacokinetics of atypical antipsychotics: an update","volume":"57","author":"Mauri","year":"2018","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0215","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s12264-016-0050-9","article-title":"Association of ABCB1 gene polymorphisms with efficacy and adverse reaction to Risperidone or Paliperidone in Han Chinese schizophrenic patients","volume":"32","author":"Mi","year":"2016","journal-title":"Neurosci. Bull."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0220","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1097\/00007691-200306000-00006","article-title":"Effects of various CYP2D6 genotypes on the steady-state plasma concentrations of risperidone and its active metabolite, 9-hydroxyrisperidone, in Japanese patients with schizophrenia","volume":"25","author":"Mihara","year":"2003","journal-title":"Ther. Drug Monit."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0225","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/bcpt.12614","article-title":"Impact of ageing on serum concentrations of Risperidone and its active metabolite in patients with known CYP2D6 genotype","volume":"119","author":"Molden","year":"2016","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0230","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/j.clpt.2005.03.009","article-title":"Effect of verapamil on pharmacokinetics and pharmacodynamics of risperidone: in vivo evidence of involvement of P-glycoprotein in risperidone disposition","volume":"78","author":"Nakagami","year":"2005","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0235","first-page":"422","article-title":"The predictive value of ABCB1, ABCG2, CYP3A4\/5 and CYP2D6 polymorphisms for risperidone and aripiprazole plasma concentrations and the occurrence of adverse drug reactions","volume":"18","author":"Rafaniello","year":"2018","journal-title":"Pharm. J."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0240","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1097\/JCP.0b013e3182408fc8","article-title":"Ketoconazole-associated preferential increase in dopamine D2 receptor occupancy in striatum compared to pituitary in vivo: role for drug transporters?","volume":"32","author":"Reist","year":"2012","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0245","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1007\/s002280100372","article-title":"Risperidone metabolism in relation to CYP2D6*10 allele in Korean schizophrenic patients","volume":"57","author":"Roh","year":"2001","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0250","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/bcpt.13031","article-title":"Effect of ABCB1 C3435T polymorphism on pharmacokinetics of antipsychotics and antidepressants","volume":"123","author":"Saiz-Rodr\u00edguez","year":"2018","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0255","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1080\/17512433.2017.1345623","article-title":"A systematic review and combined analysis of therapeutic drug monitoring studies for long- acting risperidone","volume":"10","author":"Schoretsanitis","year":"2017","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0260","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s002130051171","article-title":"Cytochrome P450 2D6 genotype and steady state plasma levels of risperidone and 9-hydroxyrisperidone","volume":"147","author":"Scordo","year":"1999","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2020.110042_bb0265","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/j.1600-0447.1970.tb02066.x","article-title":"A rating scale for extrapyramidal side effects","volume":"212","author":"Simpson","year":"1970","journal-title":"Acta Psychiatr. Scand. Suppl."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0270","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF02246543","article-title":"Influence of age, renal and liver impairment on the pharmacokinetics of risperidone in man","volume":"122","author":"Snoeck","year":"1995","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2020.110042_bb0275","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/00008571-199508000-00005","article-title":"Detection of the poor metabolizer-associated CYP2D6(D) gene deletion allele by long-PCR technology","volume":"5","author":"Steen","year":"1995","journal-title":"Pharmacogenetics"},{"key":"10.1016\/j.pnpbp.2020.110042_bb0280","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1093\/clinchem\/44.5.914","article-title":"Ultrarapid drug metabolism: PCR-based detection of CYP2D6 gene duplication","volume":"44","author":"Steijns","year":"1998","journal-title":"Clin. Chem."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0285","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/hup.1260","article-title":"Effect of the cytochrome P450 2D6*10 allele on risperidone metabolism in Japanese psychiatric patients","volume":"27","author":"Suzuki","year":"2012","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0290","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1097\/JCP.0b013e31828ecd52","article-title":"Impact of the ABCB1 gene polymorphism on plasma 9-hydroxyrisperidone and active moiety levels in Japanese patients with schizophrenia","volume":"33","author":"Suzuki","year":"2013","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0295","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1007\/s40262-015-0289-8","article-title":"Genetics-based population pharmacokinetics and pharmacodynamics of risperidone in a psychiatric cohort","volume":"54","author":"Vandenberghe","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0300","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1017\/S1461145704004390","article-title":"The brain entry of risperidone and 9-hydroxyrisperidone is greatly limited by P-glycoprotein","volume":"7","author":"Wang","year":"2004","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0305","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00213-006-0437-9","article-title":"Evaluation of antipsychotic drugs as inhibitors of multidrug resistance transporter P-glycoprotein","volume":"187","author":"Wang","year":"2006","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pnpbp.2020.110042_bb0310","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1742-7843.2008.00298.x","article-title":"Antipsychotic drugs inhibit the function of breast cancer resistance protein","volume":"103","author":"Wang","year":"2008","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0315","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s40262-015-0267-1","article-title":"Impact of genetic polymorphisms of ABCB1 (MDR1, P-glycoprotein) on drug disposition and potential clinical implications: update of the literature","volume":"54","author":"Wolking","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0320","doi-asserted-by":"crossref","first-page":"987","DOI":"10.2217\/14622416.7.7.987","article-title":"Polymorphisms of the ABCB1 gene are associated with the therapeutic response to risperidone in Chinese schizophrenia patients","volume":"7","author":"Xing","year":"2006","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.pnpbp.2020.110042_bb0325","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/0091270002239819","article-title":"Effects of CYP2D6 genotypes on plasma concentrations of risperidone and enantiomers of 9-hydroxyrisperidone in Japanese patients with schizophrenia","volume":"43","author":"Yasui-Furukori","year":"2003","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0330","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/j.1365-2125.2003.02061.x","article-title":"Effects of various factors on steady-state plasma concentrations of risperidone and 9-hydroxyrisperidone: lack of impact of MDR-1 genotypes","volume":"57","author":"Yasui-Furukori","year":"2004","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0335","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1111\/j.1476-5381.2011.01385.x","article-title":"Influence of ABCB1 genetic polymorphisms on the pharmacokinetics of risperidone in healthy subjects with CYP2D6*10\/*10","volume":"164","author":"Yoo","year":"2011","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.pnpbp.2020.110042_bb0340","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1007\/s10928-012-9253-5","article-title":"Population pharmacokinetic analysis of risperidone and 9-hydroxyrisperidone with genetic polymorphisms of CYP2D6 and ABCB1","volume":"39","author":"Yoo","year":"2012","journal-title":"J. Pharmacokinet. Pharmacodyn."}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584620303584?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584620303584?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,7]],"date-time":"2025-01-07T00:40:51Z","timestamp":1736210451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584620303584"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":68,"alternative-id":["S0278584620303584"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2020.110042","relation":{},"ISSN":["0278-5846"],"issn-type":[{"value":"0278-5846","type":"print"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ABCB1, ABCG2 and CYP2D6 polymorphism effects on disposition and response to long-acting risperidone","name":"articletitle","label":"Article Title"},{"value":"Progress in Neuro-Psychopharmacology and Biological Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pnpbp.2020.110042","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"110042"}}